We rank companies based on fund manager, research analyst and news sentiment
ADAP

Adaptimmune Therapeutics plc American Depositary Shares
ADAP

$1.16
6.98%
 

About: Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

Employees: 449

0
Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

0.39% less ownership

Funds ownership: 10.93% [Q3] → 10.54% (-0.39%) [Q4]

2% less capital invested

Capital invested by funds: $116M [Q3] → $114M (-$1.83M) [Q4]

7% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 14

1% less funds holding

Funds holding: 77 [Q3] → 76 (-1) [Q4]

48% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 27

Research analyst outlook

We haven’t received any recent analyst ratings for ADAP.

Financial journalist opinion